Cesamet (nabilone) / Viatris, Bausch Health 
Welcome,         Profile    Billing    Logout  

4 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cesamet (nabilone) / Bausch Health, Viatris
2017-004253-16: Investigation of the effect of Nabilon in patients suffering from Parkinson´s Disease with non-Motor symptoms (e.g.sleeping dirsorders, cognitive dysfunction, hallucinations, autonomic dysfunction,...)

Ongoing
3
48
Europe
Nabilone, Capsule, hard
Medizinische Universität Innsbruck, Universitätsklinik für Neurologie, AOP Orphan Pharmaceuticals AG
Subject with non-Motor symptoms of Parkinson´s disease, Parkinson´s disease, Diseases [C] - Nervous System Diseases [C10]
 
 
2015-004227-31: Clinical pilot study to review the impact of perioperative administration of the synthetic cannabinoid nabilone in the context of spinal fusion surgery on the coping with surgery and the pain perception of patients with severely reduced quality of life Klinische Pilotstudie zur Überprüfung des Einflusses einer perioperativen Einnahme des synthetischen Cannabinoids Nabilon im Rahmen stabilisierender Wirbelsäulenoperationen auf die Operationsbewältigung und das Schmerzempfinden von Patienten mit stark reduzierter Lebensqualität

Ongoing
2
36
Europe
Capsule, Canemes 1 mg Kapseln
OA Dr. Philipp Becker c/o Abteilung für Wirbelsäulenchirurgie, Orthopädisches Spital Speising GmbH, Orthopädisches Spital Speising GmbH, AOP Orphan Pharmaceuticals AG
Spine disease Wirbelsäulenerkrankung, Spine disease Wirbelsäulenerkrankung, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2017-000192-86: Investigation of the effect of Nabilon in patients suffering from Parkinson´s Disease with non-motor symptoms (e.g.sleeping disorders,cognitive dysfunction, hallucinations, autonomic dysfunction including urinary incontinence, constipation,...)

Ongoing
2
48
Europe
Nabilone, Capsule
Medizinische Universität Innsbruck, Universitätsklinik für Neurologie, AOP Orphan Pharmaceuticals AG
Subjects with non-motor symptoms of Parkinson´s disease, Parkinson´s disease, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT05494437: Effect of PP-01 on Cannabis Withdrawal Syndrome

Completed
2
234
US
PP-01 High Dose, PP-01 Low Dose, Placebo, Nabilone, Gabapentin
PleoPharma, Inc.
Cannabis Withdrawal
08/23
08/23

Download Options